Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide

被引:73
作者
Marano, RJ
Wimmer, N
Kearns, PS
Thomas, BG
Toth, I
Brankov, M
Rakoczy, PE
机构
[1] Univ Western Australia, Lions Eye Inst, Dept Mol Ophthalmol, Ctr Ophthalmol & Visual Sci, Perth, WA 6009, Australia
[2] Univ Queensland, Sch Pharm, St Lucia, Qld 4072, Australia
基金
英国医学研究理事会; 英国惠康基金;
关键词
VEGF; dendrimer; oligonucleotide; lipidic polyamide; lipoamino acids; cationic lipids; choroid; laser photocoagulation; transfection;
D O I
10.1016/j.exer.2004.06.023
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Ocular neovascularisation is the leading cause of blindness in developed countries and the most potent angiogenic factor associated with neovascularisation is vascular endothelial growth factor (VEGF). We have previously described a sense oligonucleotide (ODN-1) that possesses anti-human and rat VEGF activity. This paper describes the synthesis of lipid-lysine dendrimers and their subsequent ability to delivery ODN-1 to its target and mediate a reduction in VEGF concentration both in vitro and in vivo. Positively charged dendrimers were used to deliver ODN-1 into the nucleus of cultured D407 cells. The effects on VEGF mRNA transcription and protein expression were analysed using RT-PCR and ELISA, respectively. The most effective dendrimers in vitro were further investigated in vivo using an animal model of choroidal neovascularisation (CNV). All dendrimer/ODN-1 complexes mediated in a significant reduction in VEGF expression during an initial 24 hr period (40-60%). Several complexes maintained this level of VEGF reduction during a subsequent, second 24 hr period, which indicated protection of ODN-1 from the effects of endogenous nucleases. In addition, the transfection efficiency of dendrimers that possessed 8 positive charges (chi = 81(.)51%) was significantly better (P = 0(.)0036) than those that possessed 4 positive charges (chi = 56(.)8%). RT-PCR revealed a correlation between levels of VEGF protein mRNA. These results indicated that the most effective structural combination was three branched chains of intermediate length with 8 positive charges such as that found for dendrimer 4. Dendrimer 4 and 7/ODN-1 complexes were subsequently chosen for in vivo analysis. Fluorescein angiography demonstrated that both dendrimers significantly (P < 0(.)0001) reduced the severity of laser mediated CNV for up to two months post-injection. This study demonstrated that lipophilic, charged dendrimer mediated delivery of ODN-1 resulted in the down-regulation of in vitro VEGF expression. In addition, in vivo delivery of ODN-1 by two of the dendrimers resulted in significant inhibition of CNV in an inducible rat model. Time course studies showed that the dendrimer/ODN-1 complexes remained active for up to two months indicating the dendrimer compounds provided protection against the effects of nucleases. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:525 / 535
页数:11
相关论文
共 32 条
[21]   Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1 [J].
Liu, LX ;
Lu, HW ;
Luo, YX ;
Date, T ;
Belanger, AJ ;
Vincent, KA ;
Akita, GY ;
Goldberg, M ;
Cheng, SH ;
Gregory, RJ ;
Jiang, CW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 291 (04) :908-914
[22]  
Lobo B A, 2001, Methods Mol Med, V65, P319, DOI 10.1385/1-59259-139-6:319
[23]   SOLID PHASE PEPTIDE SYNTHESIS .1. SYNTHESIS OF A TETRAPEPTIDE [J].
MERRIFIELD, RB .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1963, 85 (14) :2149-&
[24]   The vascular endothelial growth factor mRNA contains an internal ribosome entry site [J].
Miller, DL ;
Dibbens, JA ;
Damert, A ;
Risau, W ;
Vadas, MA ;
Goodall, GJ .
FEBS LETTERS, 1998, 434 (03) :417-420
[25]   DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers [J].
Shah, DS ;
Sakthivel, T ;
Toth, I ;
Florence, AT ;
Wilderspin, AF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 208 (1-2) :41-48
[26]   Uptake dynamics and retinal tolerance of phosphorothioate oligonucleotide and its direct delivery into the site of choroidal neovascularization through subretinal administration in the rat [J].
Shen, WY ;
Rakoczy, PE .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2001, 11 (04) :257-264
[27]   RACIAL-DIFFERENCES IN THE CAUSE-SPECIFIC PREVALENCE OF BLINDNESS IN EAST BALTIMORE [J].
SOMMER, A ;
TIELSCH, JM ;
KATZ, J ;
QUIGLEY, HA ;
GOTTSCH, JD ;
JAVITT, JC ;
MARTONE, JF ;
ROYALL, RM ;
WITT, KA ;
EZRINE, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (20) :1412-1417
[28]   ANTISENSE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS - IS THE BULLET REALLY MAGICAL [J].
STEIN, CA ;
CHENG, YC .
SCIENCE, 1993, 261 (5124) :1004-1012
[29]  
Tame JRH, 1998, BIOCALORIMETRY, P27
[30]  
Urban Ernst, 2003, Farmaco (Lausanne), V58, P243, DOI 10.1016/S0014-827X(03)00022-3